Skip to main content

A phase 3 randomized study of pelabrasib (CPI-0610), a BET inhibitor, and ruxolitinib in JAK inhibitor treatment naive MF patients


Constellation Pharmaceuticals


TAP Partner

Project Term: July 31, 2012 - TBD

In July 2012, LLS began its partnership with Constellation to support three first-in-human Phase 1 clinical trials for blood cancer patients and is currently supporting "A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients." Constellation developed CPI-0610 inhibits members of the BET family of chromosome-binding proteins to selectively inactivate various cancer-promoting genes, including MYC, a master control gene that plays a role in many cancers. Inhibiting BET can kill a broad range of blood cancers. Pelabresib (CPI-0610) is currently in a registration-enabling clinical trial for the treatment of myelofibrosis.

MorphoSys acquired Constellation in July 2021 and continues to develop pelabresib in multiple clinical studies in patients with myeloproliferative neoplasms.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects